neuronal ceroid lipofuscinoses and brain abnormalities the disclosure further relates to the use of cbd in combination with one or more anti epileptic drugs application_number US 201514741829 A description the following describes the production of the highly purified gt 98 w w cannabidiol extract which has a known and constant composition which was used for the expanded access trials described in the examples below in summary the drug substance used in the trials is a liquid carbon dioxide extract of high cbd containing chemotypes of cannabis sativa l which had been further purified by a solvent crystallization method to yield cbd the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 98 cbd the cannabis sativa l plants are grown harvested and processed to produce a botanical extract intermediate and then purified by crystallization to yield the cbd drug substance the plant starting material is referred to as botanical raw material brm the botanical extract is the intermediate and the active pharmaceutical ingredient api is cbd the drug substance both the botanical starting material and the botanical extract are controlled by specifications the drug substance specification is described in table 5 below distinct chemotypes of cannabis sativa l plant have been produced to maximize the output of the specific chemical constituents the cannabinoids one type of plant produces predominantly cbd only the u2212 trans isomer occurs naturally furthermore during purification the stereochemistry of cbd is not affected an overview of the steps to produce a botanical extract the intermediate are as follows high cbd chemovars were grown harvested and dried and stored in a dry room until.